Diabetes medications and body weight
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tight diabetes control sometimes comes with a price: weight gain and hypoglycemia. Two of the three major recent trials that looked at the relationship between intensive diabetes control and cardiovascular events reported significant weight gain among the intensively treated groups. There is a growing concern that the weight gain induced by most diabetes medications diminishes their clinical benefits. On the other hand, there is a claim that treating diabetes with medications that are weight neutral or induces weight loss or less weight gain while minimizing those that increase body weight may emerge as the future direction for treating overweight and obese patients with diabetes. This review clarifies the weight effect of each of the currently available diabetes medications, and explains the mechanism of action behind this effect. Despite the great variability among reviewed clinical trials, the currently available evidence is quite sufficient to demonstrate the change in body weight in association with most of the currently available medications. This review also provides some guidelines on using diabetes medications during weight management programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Sitagliptin stabilizes postprandial GLP-1 levels; hence its net effect is mostly preventive of weight gain rather than inductive of weight loss [119].”
BackgroundWeight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“Several trials, including bariatric surgical studies [4,6,7], showed that diabetes control is significantly better after weight reduction and patients with diabetes frequently use fewer medications after weight loss [8,9].”
BackgroundBraissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Over 30 weeks, addition of exenatide to metformin, SUs or combination of both resulted in significant weight loss [109-111].”
BackgroundEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 2×
“Glulisine insulin is preferred in such scenario for being relatively quicker in its onset of action [13].”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Over 30 weeks, addition of exenatide to metformin, SUs or combination of both resulted in significant weight loss [109-111].”
BackgroundMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“Two other smaller non-randomized studies showed that metformin induces significant weight loss in patients with type 2 diabetes of different ethnicities [16,17].”
BackgroundZiccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., D’Andrea, F., Molinari, A. M., & Giugliano, D. (2002) · Circulation · doi:10.1161/hc0702.104279 · Cited by 994 · cited 1×
“It was found to be associated with increased insulin sensitivity [1] and has potential to lower blood pressure [2], serum total cholesterol and triglycerides [3] and to reduce markers of inflammation, coagulation and endothelial dysfunction [1,4,5].”
Background
Cited by
Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H. (2017) · Obesity Facts · doi:10.1159/000480525 · Cited by 431
Strojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Weight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Self-citationHamdy, O., Mottalib, A., Morsi, A., El-Sayed, N., Goebel-Fabbri, A., Arathuzik, G., Shahar, J., Kirpitch, A., & Zrebiec, J. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000259 · Cited by 87
Self-citation
Metadata
- Authors
- Mitri, J., & Hamdy, O.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2009-06-21
- Volume
- 8
- Issue
- 5
- Pages
- 573-584
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2031723890
- Cited by
- 135
- References
- 31
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes medications and body weight. https://app.cochat.ai/papers/10.1517/14740330903081725
- The paper
- Mitri, J., & Hamdy, O. (2009). Diabetes medications and body weight. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740330903081725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.